Heron Therapeutics, Inc. Q2 FY2026 earnings call

• Balance Sheet Adjustment Post Court Ruling

  • The U.S. District Court of Delaware's June 2026 ruling on Sinvanti patents materially changed the company's outlook. Management amended its credit facility with Hercules to reset debt covenants through 2027 to align with the company's revised operating plan, and agreed to a total potential principal reduction of $17.5 million.
  • The company ended Q2 2026 with $42.7 million in total cash, cash equivalents and short-term investments; pro forma cash is approximately $28.5 million after the first principal payment, and will drop to ~$24.3 million after the scheduled September 2026 payment.

• Cost Control Actions

  • Management paused the planned Salesforce expansion for H2 2026 after the court ruling, and is now holding spending tightly while the competitive landscape for Sinvanti clarifies. Spending decisions will be tied to actual business performance rather than the pre-ruling plan.

• Intellectual Property and Competitive Defense

  • The company has filed an appeal of the June patent ruling. While no generic version of Sinvanti has launched yet, management is proactively executing a defense strategy to prepare for potential generic entry, centered on Sinvanti's clinical profile, existing customer relationships, and pre-positioned contracting.

• Strategic Review

  • The board and management are actively evaluating strategic alternatives alongside execution of the current operating plan. No timetable has been set for the process, there is no guarantee a transaction will result, and no further comments will be provided unless legally required or appropriate.

• Operational Commercial Highlights

  • Zenderlev average daily units grew 19% year-over-year, with the Ignite 2.0 program active across 3,150 accounts, up from 2,260 accounts in Ignite 1.0. Adoption is proceeding on a site-by-site basis, and growth was slower than planned in Q2. Aponvy hit 23% NK1 segment share with 59% year-over-year average daily unit growth. Sinvanti utilization has held steady over two years, with a 25% June 2026 share in line with its 12-month average.

Heron Therapeutics reports total net revenue of $37.7 million for Q2 2026, split across two core segments:

1. Acute Care Franchise: Combined net revenue of $15.3 million (40.6% of total net revenue), with 44% year-over-year growth. This includes Zenderlev at $11.1 million (29.4% of total net revenue), up 35% year-over-year and 9% quarter-over-quarter; and Aponvy at $4.2 million (11.1% of total net revenue), up 74% year-over-year and 26% quarter-over-quarter. Aponvy now holds 23% share of the surgical NK1 segment, up 2 percentage points from Q1 2026.
2. Oncology Franchise: Combined net revenue of $22.3 million (59.2% of total net revenue). This includes Sinvanti at $21.8 million (57.8% of total net revenue), up 6.3% quarter-over-quarter but down 10% year-over-year due to existing brand competition; and Sustol at $0.5 million (1.3% of total net revenue), which is in a planned wind-down phase.

• Management withdrew its original full-year 2026 guidance that projected $173 to $183 million in net product sales and $10 to $20 million in adjusted EBITDA, as the original guidance is no longer reliable given recent events.
• Three key factors led to the withdrawal: the uncertain timing and terms of potential generic entry for Sinvanti (the company's largest product), the decision to pause the previously planned Salesforce expansion and tighten H2 2026 spending, and the ongoing evaluation of strategic alternatives. The withdrawal is a forecasting decision, not a reflection of underlying business performance.
• Going forward, the company will instead provide quarterly updates on cash position, operating spending, and debt covenant compliance, rather than issuing full-year annual guidance at this time.

• Uncertainty around the outcome of the Sinvanti patent appeal and the timing, scale, and impact of potential generic entry for the company's largest revenue-generating product.
• Commercial underperformance relative to internal expectations for both Zenderlev and Sinvanti even before any generic entry, driven by a highly competitive market and slower-than-planned adoption in existing accounts.
• Debt covenant compliance risk, mitigated by the recent amendment that resets covenants through 2027 on a more conservative basis that accounts for potential generic entry.
• Uncertainty around the outcome of the ongoing strategic alternatives review, with no guarantee that a value-enhancing transaction will be completed.

Q: Can management confirm confidence in meeting the revised debt covenants even if a Sinvanti generic launches, explain why generic erosion would differ from Sustol's wind-down, and what is driving Zenderlev's below-expectation performance? / A: Management built a very conservative assumption of an early, large-scale generic launch into the amended covenants, which lenders approved. Generic launch timing and scale is uncertain because the product requires complex sterile emulsion manufacturing that takes time to scale to the current 750,000-800,000 annual unit volume, and reimbursement J-code status for generics is also unresolved. For Zenderlev, the product still grew 9% quarter-over-quarter, but Q2 market growth was slower than expected; management noted the underperformance is an execution issue to fix in Q3, not a product adoption problem, and still expects stronger growth in the back half of the year, which is the typical seasonal pattern for the category.

Q: What impact would an Azurity generic Sinvanti launch have on the company's existing Sinvanti settlement agreements with other potential generic entrants? / A: Management confirmed that an Azurity generic launch would have no impact at all on the existing settlement agreements with other players, and the terms of those settlements remain unchanged regardless of whether any generic enters the market.

Q: Is Zenderlev's slowdown in Q2 tied to broader macro volatility impacting surgical volumes and healthcare spending, as reported by a competitor? / A: Management noted that the company continued to win new P&T formulary approvals throughout Q2, and did not see material impact from the reported macro healthcare volatility. The slowdown was simply due to slower-than-expected pull-through of adoption in existing accounts during the quarter, and management expects this progress to pick up in the back half of 2026.